Program
HRS-7058
A development code. Also written as “HRS-7058 capsule/ HRS-7058 tablet”, “Adebrelimab Injection combined with HRS-7058 Capsule” and “HRS-7058 + SHR-1316”.
In Jiangsu HengRui Medicine's pipeline, KRAS G12C
. Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Pancreatic Neoplasms, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 66 open or running | phase 3since May 15, 2026 | Apr 19, 2024 | Dec 2026phase 2 · NCT06915142 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-7058
, phase 3, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 19, 2024First study: phase 1 study in Advanced Malignant TumourFirst studyNCT06383871 · 233 planned · China
- Apr 1, 2025Phase 2 study in Advanced Malignant TumourNCT06915142 · 300 planned · China
- Jun 13, 2025Phase 2 study in Solid TumorsNCT07032077 · 100 planned · China
- May 9, 2026Phase 2 study in Pancreatic NeoplasmsNCT07589569 · 92 planned · China
- May 15, 2026Phase 3 study in KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard TreatmentPhase 3 reachedNCT07601048 · 450 planned · China
- Jul 10, 2026Phase 2 study in Resectable Non-small Cell Lung CancerNCT07704645 · 180 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in Advanced Malignant TumourNCT06915142
- Jun 2027Primary completion: phase 2 study in Solid TumorsNCT07032077
- May 2028Primary completion: phase 3 study in KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard TreatmentNCT07601048
- Jun 2028Primary completion: phase 2 study in Resectable Non-small Cell Lung CancerNCT07704645
TargetBeta
“KRAS G12C”the company's pipeline, read by Claude · source
“This is a multicenter, open-label, single-arm, phase II cilinical trial designed to evaluate the efficacy and safety of the KRAS G12C selective inhibitor HRS-7058 in patients with KRAS G12C-mutated advanced pancreatic cancer who had failed 1-2 lines of previous systemic therapy.”study summary, read by Claude · the study
Other programs on KRAS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sotorasibrule | Amgen | phase 3 | 28 |
| adagrasibrule | Bristol-Myers Squibb | phase 3 | 16 |
| olomorasib | Eli Lilly | phase 3 | 16 |
| divarasib | Hoffmann-La Roche | phase 3 | 13 |
| KRAS G12D Inhibitor VS-7375rule | Genfleet Therapeutics (Shanghai) | phase 3 | 12 |
| glecirasibrule | Allist Pharmaceuticals | phase 3 | 12 |
| calderasib | Merck | phase 3 | 12 |
| daraxonrasibrule | Revolution Medicines | phase 3 | 10 |
| garsorasibrule | InventisBio | phase 3 | 8 |
| KRAS G12D Inhibitor HRS-4642 | Jiangsu HengRui Medicine | phase 3 | 7 |
| zoldonrasibrule | Revolution Medicines | phase 3 | 6 |
| opnurasibrule | Novartis | phase 3 | 5 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07704645Resectable Non-small Cell Lung Cancer · China | 2 | Not yet recruiting | Jun 2028 | 180 |
| NCT07601048KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment · China | 3 | Not yet recruiting | May 2028 | 450 |
| NCT07589569Pancreatic Neoplasms · China | 2 | Recruiting | Dec 2028 | 92 |
| NCT07032077Solid Tumors · China | 2 | Recruiting | Jun 2027 | 100 |
| NCT06915142Advanced Malignant Tumour · China | 2 | Recruiting | Dec 2026 | 300 |
| NCT06383871Advanced Malignant Tumour · China | 1 | Recruiting | Jun 2026 | 233 |
How it is read
Names in the registry
- “HRS-7058”, 3 entries
- “HRS-7058 capsule/ HRS-7058 tablet”, 2 entries
- “Adebrelimab Injection combined with HRS-7058 Capsule”, 1 entry
- “HRS-7058 + SHR-1316”, 1 entry
- “HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy”, 1 entry
Codes read as this program: HRS7058.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Pancreatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.